Clinical Trials - Phase I
Filter News
Found 21,047 articles
-
R-Tech Ueno: Completion Of A Phase I/II Clinical Study Of Recombinant Human Serum Albumin-Containing Ophthalmic Solution (Development Code: RU-101) In The U.S. For The Treatment Of Severe Dry Eye
11/10/2014
-
NeuralStem Inc. Announces Publication Of Long Term Cell Survival From Phase I NSI-566 ALS Study In The Journal "Annals Of Clinical And Translational Neurology"
11/10/2014
-
Novavax, Inc. Initiates Phase 1 Clinical Trial Of RSV F Vaccine In Pediatric Subjects
11/10/2014
-
Galectin Therapeutics' Phase 1 Data Presented At American Association for Study of Liver Diseases Annual Meeting Advances GR-MD-02 Into Phase 2 Clinical Development
11/10/2014
-
EnGeneIC Pty Ltd And Asbestos Diseases Research Institute Initiate Mesomir-1 Phase 1 Trial In Patients With Late Stage Mesothelioma
11/10/2014
-
Novira Therapeutics Announces Presentation Of Phase 1a Safety And Pharmacokinetic Data For NVR 3-778
11/10/2014
-
Anavex Life Sciences Corp. To Present Full Phase 1 Clinical Trial Data For ANAVEX 2-73 At CNS Summit 2014 Conference
11/10/2014
-
Seattle Children's Research Institute's Begins Recruiting Patients For Immunotherapy Research Trial For Neuroblastoma, One Of The Deadliest Forms Of Childhood Cancer
11/7/2014
-
Merrimack Pharmaceuticals Inc. Announces Initiation Of Phase 1 Clinical Study Of MM-398 For Brain Cancer
11/6/2014
-
Perosphere Inc.’s Anticoagulant Reversal Agent Clinical Trial Results Published In The New England Journal of Medicine
11/6/2014
-
Epizyme Reports Publication Of Preliminary Findings from Phase 1 Study Of DOT1L Inhibitor EPZ-5676 In American Society of Hematology Annual Meeting Abstract
11/6/2014
-
Cornerstone Pharmaceuticals, Inc. Announces Positive Phase I Data For CPI-613 In Relapsed Or Refractory AML Patients To Be Presented At 2014 American Society of Hematology Annual Meeting
11/6/2014
-
FDA Grants Orphan Drug Designation To Merrimack Pharmaceuticals Inc.' MM-141 For The Treatment Of Pancreatic Cancer
11/5/2014
-
BioLineRx Ltd. Announces Successful Final Results Of Phase 1/2 Study For Novel Celiac Treatment
11/5/2014
-
BerGenBio AS Announces First Patient Dosed in BGB324 AML Trial
11/4/2014
-
Ruthigen Announces First Patient Enrollment In The Phase 1/2 Human Clinical Trial Of RUT58-60, A Broad-Spectrum Anti-Infective Drug Candidate Designed For Prophylactic Use During Invasive Surgery
11/4/2014
-
Que Oncology Announces Positive Phase 1 Results With Q-122
11/4/2014
-
Edge Therapeutics Initiates Enrollment Of Third Cohort In Phase 1/2 NEWTON Study Of EG-1962 For Improvement Of Outcome After Ruptured Brain Aneurysm
11/4/2014
-
Theravance Biopharma Announces Positive Results From Phase 1 Proof-of-Concept Study Of TD-6450, An NS5A Inhibitor To Treat Hepatitis C
11/4/2014
-
SAGE Therapeutics Release: First Evaluation Of SAGE-547 To Treat Super-Refractory Status Epilepticus In Children Published In Annals Of Neurology
11/3/2014